Anti-tumor and anti-leishmanial evaluations of 1,3,4-oxadiazine, pyran derivatives derived from cross-coupling reactions of ?-bromo-6H-1,3,4- oxadiazine derivatives

Simple item page
dc.AffiliationOctober University for modern sciences and Arts (MSA)
dc.contributor.authorMohareb R.M.
dc.contributor.authorSchatz J.
dc.contributor.otherFaculty of Pharmacy
dc.contributor.otherOrganic Chemistry Department
dc.contributor.otherOctober University for Modern Science and Arts University
dc.contributor.otherEl-Wahaat Road
dc.contributor.otherOctober City
dc.contributor.otherEgypt; Department of Chemistry
dc.contributor.otherFaculty of Science
dc.contributor.otherCairo University
dc.contributor.otherGiza
dc.contributor.otherA.R.
dc.contributor.otherEgypt; Department Chemie und Pharmazie - Organische Chemie i
dc.contributor.otherFriedrich-Alexander-Universit�t Erlangen-N�rnberg
dc.contributor.otherHenkestra�e 42
dc.contributor.otherD-91054 Erlangen
dc.contributor.otherGermany
dc.date.accessioned2020-01-25T19:58:31Z
dc.date.available2020-01-25T19:58:31Z
dc.date.issued2011
dc.descriptionScopus
dc.description.abstractCyanoacetylhydrazine reacted with the ?-bromoacetophenones 2a,b to give hydrazide-hydrazone derivatives 3a,b. The latter products were cyclized to the 1,3,4-oxadiazine derivatives 4a,b. Bromination of the latter products gave the 6-bromo-6H-1,3,4-oxadiazine derivatives 5a,b which underwent a series of cross-coupling reactions. The antitumor evaluation of the newly synthesized products against the three cancer cells namely breast adenocarcinoma (MCF-7), non-small cell lung cancer (NCI-H460) and CNS cancer (SF-268) showed that some of them have high inhibitory effect towards three cell lines which is higher than the standard. Moreover, the anti-leishmanial activity of the newly synthesized product was tested on Leishmania donovani amastigotes showed that some compounds have high activity. � 2011 Published by Elsevier Ltd. All rights reserved.en_US
dc.description.urihttps://www.scimagojr.com/journalsearch.php?q=25786&tip=sid&clean=0
dc.identifier.doihttps://doi.org/10.1016/j.bmc.2011.02.051
dc.identifier.doiPubMed ID 21435889
dc.identifier.issn9680896
dc.identifier.otherhttps://doi.org/10.1016/j.bmc.2011.02.051
dc.identifier.otherPubMed ID 21435889
dc.identifier.urihttps://t.ly/ZEKZB
dc.language.isoEnglishen_US
dc.relation.ispartofseriesBioorganic and Medicinal Chemistry
dc.relation.ispartofseries19
dc.subject1,3,4-Oxadiazineen_US
dc.subjectAnti-leishmanialen_US
dc.subjectAnti-tumoren_US
dc.subjectCross-couplingen_US
dc.subjectHydrazide-hydrazoneen_US
dc.subjectPyranen_US
dc.subject1,3,4 oxadiazine derivativeen_US
dc.subject2 (4 bromoacetophenon omega yl) 3 (4 bromophenyl) 5 cyano 6 cyanomethylpyranen_US
dc.subject2 (4 bromoacetophenon omega yl) 3 (4 nitrophenyl) 5 cyano 6 cyanomethylpyranen_US
dc.subject2 (4 nitroacetophenon omega yl) 3 (4 bromophenyl) 5 cyano 6 cyanomethylpyranen_US
dc.subject2 (4 nitroacetophenon omega yl) 3 (4 nitrophenyl) 5 cyano 6 cyanomethylpyranen_US
dc.subject2 [5 (4 bromophenyl) 6 (4 bromophenylacet omega yl) 6h 1,3,4 oxadiazin 2 yl]acetonitrileen_US
dc.subject2 [5 (4 bromophenyl) 6 bromo 6h 1,3,4 oxadiazin 2 yl]acetonitrileen_US
dc.subject2 [5 (4 bromophenyl) 6h 1,3,4 oxadiazin 2 yl]acetonitrileen_US
dc.subject2 [5 (4 nitrophenyl) 6 (4 bromophenylacet omega yl) 6h 1,3,4 oxadiazin 2 yl]acetonitrileen_US
dc.subject2 [5 (4 nitrophenyl) 6 (4 nitrophenylacet omega yl) 6h 1,3,4 oxadiazin 2 yl]acetonitrileen_US
dc.subject2 [5 (4 nitrophenyl) 6 bromo 6h 1,3,4 oxadiazin 2 yl]acetonitrileen_US
dc.subject2 [5 (4 nitrophenyl) 6h 1,3,4 oxadiazin 2 yl]acetonitrileen_US
dc.subjectamphotericin Ben_US
dc.subjectcyanoacetylhydrazido n (4 bromophenyl alpha bromoaceto)hydrazoneen_US
dc.subjectcyanoacetylhydrazido n (4 nitrophenyl alpha bromoaceto)hydrazoneen_US
dc.subjectdoxorubicinen_US
dc.subjecthydrazide derivativeen_US
dc.subjecthydrazone derivativeen_US
dc.subjectunclassified drugen_US
dc.subjectamastigoteen_US
dc.subjectantineoplastic activityen_US
dc.subjectarticleen_US
dc.subjectbrominationen_US
dc.subjectcancer cellen_US
dc.subjectcell strain MCF 7en_US
dc.subjectcontrolled studyen_US
dc.subjectcross coupling reactionen_US
dc.subjectcyclizationen_US
dc.subjectcycloadditionen_US
dc.subjectdrug structureen_US
dc.subjectgrowth inhibitionen_US
dc.subjecthumanen_US
dc.subjecthuman cellen_US
dc.subjectLeishmania donovanien_US
dc.subjectnonhumanen_US
dc.subjectSuzuki reactionen_US
dc.subjectAntineoplastic Agentsen_US
dc.subjectCell Line, Tumoren_US
dc.subjectCyclizationen_US
dc.subjectDrug Screening Assays, Antitumoren_US
dc.subjectHalogenationen_US
dc.subjectHeterocyclic Compoundsen_US
dc.subjectHumansen_US
dc.subjectHydrazonesen_US
dc.subjectLeishmaniaen_US
dc.subjectParasitic Sensitivity Testsen_US
dc.subjectPyransen_US
dc.subjectLeishmania donovanien_US
dc.titleAnti-tumor and anti-leishmanial evaluations of 1,3,4-oxadiazine, pyran derivatives derived from cross-coupling reactions of ?-bromo-6H-1,3,4- oxadiazine derivativesen_US
dc.typeArticleen_US
dcterms.isReferencedByShindy, H.A., El-Maghraby, M.A., Eissa, F.M., (2006) Dyes Pigm., 70, p. 110; Mazouz, F., Lebreton, L., Milcent, R., Burstein, C., (1988) Eur. J. Med. Chem., 23, p. 441; Forchiassin, M., Risaliti, A., Russo, C., (1981) Tetrahedron, 37, p. 2921; Yamazaki, N., Kibayashi, C., (1997) Tetrahedron Lett., 26, p. 4623; Singh, S., K, L.H., Athar, F., Azam, A., (2005) Eur. J. Pharm. Sci., 25, p. 255; Kaleta, K., Fleischhauer, J., G�rls, H., Beckert, R., Imhof, W.J., (2009) Organomet. Chem., 23, p. 3800; Muehlebach, M., Boeger, M., Cederbaum, F., Cornes, D., Friedmann, A.A., Glock, J., Niderman, T., Wagner, T., (2009) Bioorg. Med. Chem., 17, p. 4241; Ke, S.Y., Liu, Q.X., Wang, N., Yang, Q., Li, Z., (2009) Eur. J. Med. Chem., 44, p. 2113; Bor�n, L., Martin-Matute, B., Xu, Y., Cordova, A., B�ckvall, J.E., (2006) Chem. Eur. J., 12, p. 225; Srivastava, R.M., De Morais, L.P., De Melo, S.C., Souto, G.B., Carpenter De Carvalho, L.T., (2006) Tetrahedron Lett., 47, p. 3173; Saracoglu, N., (2007) Tetrahedron, 63, p. 4199; Tahdi, A.S., Titouani, L., Soufiaoui, M., Komiha, N., Kabbaj, O.K., Hegazi, S., Mazzah, A., Eddaif, A., (2002) Tetrahedron, 58, p. 1507; Todd, L., Graybill, R.E., Carla, T., Helaszek, M.A., Ator, J.S., (1995) Bioorg. Med. Chem. Lett., 5, p. 1197; Frank, G., Riddell, E., Turner, S., (1979) Tetrahedron, 35, p. 1311; Wiessler, M., (1975) Tetrahedron Lett., 16, p. 2575; Muehlebach, M., Boeger, M., Cederbaum, F., Cornes, D., Friedmann, A.A., Glock, J., Niderman, T., Wagner, T., (2009) Bioorg. Med. Chem., 17, p. 4241; Vasiliev, N.V., Lyashenko, Y.E., Patalakha, A.E., Sokolski, G.A., (1993) J. Fluorine Chem., p. 227; Moody, C.J., (1982) Adv. Heterocycl. Chem., 30, p. 1; Padwa, A., Eisenbarth, P., (1985) Tetrahedron, 41, p. 283; Riddell, F.G., Turner, E.S., (1979) Tetrahedron, 35, p. 1311; Tiecco, M., Testaferri, L., Marini, F., (1996) Tetrahedron, 52, p. 11841; Job, A., Janeck, C.F., Bettray, W., Peters, R., Enders, D., (2002) Tetrahedron, 58, p. 2253; Mohamed, A.A., Radwan, M.E., (2007) Bioorg. Med. Chem., 15, p. 1206; Muehlebach, M., Boeger, M., Cederbaum, F., Cornes, D., Friedmann, A.A., Glock, J., Niderman, T., Wanger, T., (2009) Bioorg. Med. Chem., 17, p. 4241; Von Angerer, E., Strohmeier, J., (1987) J. Med. Chem., 30, p. 131; Glamkowski, E.J., Fortunato, J.M., Spaulding, T.C., Wilker, J.C., Ellis, D.B., (1985) J. Med. Chem., 28, p. 66; Unangst, P.C., Carethers, M.E., Webster, K., Janik, G.M., Robichaud, L.J., (1984) J. Med. Chem., 27, p. 1629; Sano, H., Noguchi, T., Miyajima, A., Hashimoto, Y., Miyachi, H., (2006) Bioorg. Med. Chem. Lett., 16, p. 3068; Perregaard, J., Arnt, J., Boegesoe, K.P., Hyttel, J., Sanchez, C., (1992) J. Med. Chem., 35, p. 1092; Cole, D.C., Ellingboe, J.W., Lennox, W.J., Mazandarani, H., Smith, D.L., Stock, J.R., Zhang, G.M., Schechter, L.E., (2005) Bioorg. Med. Chem. Lett., 15, p. 379; Li, Q., Li, T.M., Woods, K.W., Gu, W.Z., Cohen, J., Stoll, V.S., Galicia, T., Sham, H.L., (2005) Bioorg. Med. Chem. Lett., 15, p. 2918; Xu, H., Liu, W.Q., Fan, L.L., Chen, Y., Yang, L.M., Lv, L., Zheng, Y.T., (2008) Chem. Pharm. Bull., 56, p. 720; Hermecz, I., (2003) Adv. Heterocycl. Chem., 65, p. 173; Ternon, M., Outurquin, F., Paulmier, C., (2001) Tetrahedron, 57, p. 10259; Mohareb, R.M., Mohamed, A.A., (2010) Molecules, 15, p. 3602; Mohareb, R.M., El-Arab, E.E., El-Sharkawy, K.A., (2009) Sci. Pharm., 77, p. 355; Batty, D., Langlois, Y., (1993) Tetrahedron Lett., 34, p. 457; Kennedy, J.W., Hall, D.G.J., (2003) Organomet. Chem., 680, pp. 263-270
dcterms.sourceScopus

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
avatar_scholar_256.png
Size:
6.31 KB
Format:
Portable Network Graphics
Description:
Download

Collections

Faculty Of Pharmacy Research Paper